The European Science Foundation said it will propose a comprehensive mental health research effort of a size similar to that of the Human Genome Project.
The proposal -- to be discussed during the Foundation's annual EuroBioForum in Lisbon, Portugal -- is aimed at making Europe the global leader of research in the critical role of neurotransmitters in brain disorders.
Foundation officials said the project would bring together the efforts of scientists from a broad array of specialized areas, such as biochemistry, molecular biology, psychopharmacology and imaging techniques.
Professor David Nutt of the University of Bristol will lead the project to develop new methods of identifying the release of neurotransmitters, such as serotonin and dopamine, in the brain. Researchers would thenbe better able to examine the role of neurotransmitters in major mental disorders, including depression and schizophrenia.
Despite the vast number of affected people, Nutt said, "We don't even know … whether serotonin levels are high or low in depressed people."
He said he believes the conference will help people from universities, governments, industry and funding organizations to "share ideas and contribute to key policy and funding decisions."
The EuroBioForum meeting will run Wednesday through Friday.
Copyright 2007 by United Press International
Related stories:
Biophysicists create new model for protein-cholesterol interactions in brain and muscle tissue
Biophysicists at the University of Pennsylvania have used 3,200 computer processors and long-established data on cholesterol's role in the function of proteins to clarify the mysterious interaction between cholesterol and neurotransmitter receptors. The results provide a new model of behavior for the nicotinic acetylcholine receptor, a well studied protein involved in inflammation, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, the effect of general anesthetics and addiction to alcohol, nicotine and cocaine.
The first autism disease genes
The autistic disorder was first described, more than sixty years ago, by Dr. Leo Kanner of the Johns Hopkins Hospital (USA), who created the new label 'early infantile autism'. At the same time an Austrian scientist, Dr. Hans Asperger, described a milder form of the disorder that became known as Asperger Syndrome, characterised by higher cognitive abilities and more normal language function. Today, both disorders are classified in the continuum of 'Pervasive Developmental Disorders' (PDD), more often referred to as Autism Spectrum Disorders (ASD).
Probing Question: Fishhooks of addiction
When the American writer Theodore Roethke taught at Penn State from 1936 to 1943, he was known for three things: being a good poet, coaching the men’s tennis team, and falling down drunk, perhaps the latter more than the former. Roethke, a brilliant and tortured man, knew well the seduction of drink and the agony of addiction. In his poem “Journey Into the Interior,” Roethke writes, “In the long journey out of the self, / There are many detours, washed-out interrupted raw places / Where the shale slides dangerously / And the back wheels hang almost over the edge / At the sudden veering, the moment of turning.”
Eating and weight gain not necessarily linked, study shows
You may not be what you eat after all. A new study shows that increased eating does not necessarily lead to increased fat. The finding in the much-studied roundworm opens the possibility of identifying new targets for drugs to control weight, the researchers say.
Are anxiety disorders all in the mind?
Using single-photon emission computed tomography (SPECT), researchers in The Netherlands were able to detect biochemical differences in the brains of individuals with generalized social anxiety disorder (also known as social phobia), providing evidence of a long-suspected biological cause for the dysfunction.
Depression diversity: Brain studies reveal big differences among individuals
Depressed people may have far fewer of the receptors for some of the brain’s “feel good” stress-response chemicals than non-depressed people, new University of Michigan Depression Center research shows.
Researchers may have found test for depression
Researchers from the University of Illinois at Chicago College of Medicine have discovered that a change in the location of a protein in the brain could serve as a biomarker for depression, allowing a simple, rapid, laboratory test to identify patients with depression and to determine whether a particular antidepressant therapy will provide a successful response. The research is published in the March 12 issue of the
Journal of Neuroscience.
Deafness and seizures result when mysterious protein deleted in mice
Scientists have discovered that mice genetically engineered to lack a particular protein in the brain have profound deafness and seizures. The finding suggests a pathway, they say, for exploring the hereditary causes of deafness and epilepsy in humans.